Your browser doesn't support javascript.
loading
The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.
Paterson, Louise M; Flechais, Remy S A; Murphy, Anna; Reed, Laurence J; Abbott, Sanja; Boyapati, Venkataramana; Elliott, Rebecca; Erritzoe, David; Ersche, Karen D; Faluyi, Yetunde; Faravelli, Luca; Fernandez-Egea, Emilio; Kalk, Nicola J; Kuchibatla, Shankar S; McGonigle, John; Metastasio, Antonio; Mick, Inge; Nestor, Liam; Orban, Csaba; Passetti, Filippo; Rabiner, Eugenii A; Smith, Dana G; Suckling, John; Tait, Roger; Taylor, Eleanor M; Waldman, Adam D; Robbins, Trevor W; Deakin, J F William; Nutt, David J; Lingford-Hughes, Anne R.
Afiliación
  • Paterson LM; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Flechais RS; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Murphy A; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
  • Reed LJ; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Abbott S; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
  • Boyapati V; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
  • Elliott R; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
  • Erritzoe D; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Ersche KD; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Faluyi Y; Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Faravelli L; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Fernandez-Egea E; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Kalk NJ; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Kuchibatla SS; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
  • McGonigle J; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Metastasio A; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK 5 Boroughs Partnership NHS Foundation Trust, Warrington, UK.
  • Mick I; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Nestor L; Centre for Neuropsychopharmacology, Imperial College London, London, UK Clinical Research Unit, GlaxoSmithKline, Cambridge, UK.
  • Orban C; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
  • Passetti F; Centre for Neuropsychopharmacology, Imperial College London, London, UK Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Rabiner EA; Imanova Ltd, London, UK.
  • Smith DG; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychology, University of Cambridge, Cambridge, UK.
  • Suckling J; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
  • Tait R; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK.
  • Taylor EM; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
  • Waldman AD; Centre for Neuroinflammation and Neurodegeneration, Imperial College London, London, UK.
  • Robbins TW; Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK Department of Psychology, University of Cambridge, Cambridge, UK.
  • Deakin JF; Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.
  • Nutt DJ; Centre for Neuropsychopharmacology, Imperial College London, London, UK d.nutt@imperial.ac.uk.
  • Lingford-Hughes AR; Centre for Neuropsychopharmacology, Imperial College London, London, UK.
J Psychopharmacol ; 29(9): 943-60, 2015 Sep.
Article en En | MEDLINE | ID: mdl-26246443
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Conducta Adictiva / Trastornos Relacionados con Sustancias / Investigación Biomédica / Prevención Secundaria Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Psychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Preparaciones Farmacéuticas / Conducta Adictiva / Trastornos Relacionados con Sustancias / Investigación Biomédica / Prevención Secundaria Tipo de estudio: Clinical_trials Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: J Psychopharmacol Asunto de la revista: PSICOFARMACOLOGIA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido